Solid Biosciences CEO to Share Insights at Key Healthcare Event
Solid Biosciences Inc. (NASDAQ: SLDB), a leader in the field of precision genetic medicine, is making waves as it prepares to present at a prestigious healthcare conference. The company is known for its innovative approach to developing treatments for complex neuromuscular and cardiac diseases.
Conference Presentation and Webcast Details
On January 15, 2025, Bo Cumbo, the President and CEO of Solid Biosciences, will take center stage at the 43rd Annual J.P. Morgan Healthcare Conference. He is scheduled to present at 3:45 p.m. PT, providing valuable insights into the company's ongoing projects and future ambitions. This event is a key gathering for investors, analysts, and industry leaders who are keen on advancing healthcare technologies.
Accessing the Live Event
For those unable to attend in person, Solid Biosciences will offer a live webcast of the presentation. Investors and interested parties can access it through the Events page of the company’s website. Additionally, a replay of the webcast will be available for 30 days, ensuring that everyone has the opportunity to stay informed about the company’s developments.
Engaging with Institutional Investors
During the conference, opportunities for meetings will be available for institutional investors seeking to connect with Solid’s management team. Those interested are encouraged to coordinate through their J.P. Morgan representatives to facilitate discussions regarding potential investments and partnerships.
About Solid Biosciences
Solid Biosciences has cultivated a reputation as a pioneer in developing precision genetic medicines aimed at treating a variety of serious conditions. The company’s pipeline includes gene therapy candidates targeting Duchenne muscular dystrophy (Duchenne), Friedreich's ataxia, catecholaminergic polymorphic ventricular tachycardia (CPVT), and various forms of dilated cardiomyopathy. By addressing these often-overlooked diseases, Solid aims to enhance the quality of life for patients and their families.
Commitment to Patients
Solid's dedication extends beyond research and development; the company was founded by individuals affected by these diseases. This unique perspective fuels their mission to improve patient outcomes and redefine the standard of care. Solid is committed to advancing science while keeping the patient experience at the forefront.
Contact Information for Investors and Media
For inquiries related to investor relations, Nicole Anderson serves as the Director of Investor Relations and Corporate Communications. Interested parties can reach her via email at investors@solidbio.com. Media inquiries can be directed to Glenn Silver at FINN Partners, with contact available at glenn.silver@finnpartners.com.
Frequently Asked Questions
What is the purpose of Solid Biosciences' presentation at the conference?
Bo Cumbo, the CEO, will discuss the company's advancements in genetic medicines for neuromuscular and cardiac diseases.
How can I watch the presentation?
The presentation will be available via a live webcast on Solid Biosciences' website.
What diseases does Solid Biosciences focus on?
The company primarily targets neuromuscular and cardiac diseases, including Duchenne muscular dystrophy and certain cardiomyopathies.
Who can meet with the management team during the conference?
Institutional investors can arrange meetings with Solid’s management through their J.P. Morgan representatives.
How does Solid Biosciences prioritize patient care?
The company was founded by individuals who faced these diseases directly, emphasizing a patient-centered approach in their mission.
